✦ LIBER ✦

A Step-wise Approach for Transfer of Immunogenicity Assays during Clinical Drug Development

✍ Scribed by Suzanna Tatarewicz; Michael Moxness; Dohan Weeraratne; Lei Zhou; Michael Hale; Steven J. Swanson; Narendra Chirmule

Book ID: 111767584
Publisher: American Association of Pharmaceutical Scientists
Year: 2009
Tongue: English
Weight: 180 KB
Volume: 11
Category: Article
ISSN: 1550-7416
DOI: 10.1208/s12248-009-9130-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Solution ELISA as a platform of choice f

Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development

✍ Alvydas Mikulskis; Dave Yeung; Meena Subramanyam; Lakshmi Amaravadi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 523 KB

Development of a 1-step cell-based assay

Development of a 1-step cell-based assay for cost-effective screening of antiviral drugs for vaccinia virus

✍ Desyreé M. Jesus; Élida S. Santos; Laila C. Schnellrath; Clarissa R. Damaso 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 668 KB

194 Translating interesting biology into

194 Translating interesting biology into clinically useful tools — the need for a systematic approach to quality control during the development of predictive assays in radiation oncology

✍ A. Munro; E. Brown; M. Nashed; P. Bryant; H. MacDougall 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 265 KB

Development of a replicon-based phenotyp

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates

✍ Xiaoping Qi; Andrew Bae; Shan Liu; Huiling Yang; Siu-Chi Sun; Jeanette Harris; W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4

Development of a one-step real-time quan

Development of a one-step real-time quantitative PCR assay based on primer-probe energy transfer for the detection of porcine reproductive and respiratory syndrome virus

✍ Gyula Balka; Ákos Hornyák; Ádám Bálint; Zsófia Benyeda; Miklós Rusvai 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 538 KB